公开(公告)号：US11414404B2

公开(公告)日：2022-08-16

申请号：US16910688

申请日：2020-06-24

Applicant: Array BioPharma Inc.

Inventor： Patrick Michael Barbour ,  Katie Keaton Brown ,  Adam Wade Cook ,  Erik James Hicken ,  Dean Russell Kahn ,  Ellen Ruth Laird ,  Andrew Terrance Metcalf ,  David Austin Moreno ,  Bradley Jon Newhouse ,  Spencer Phillip Pajk ,  Brett Joseph Prigaro ,  Li Ren ,  Eugene Tarlton

IPC: C07D403/12 ,  C07D239/90 ,  C07D239/91 ,  A61K31/4184 ,  A61K45/06

Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

公开(公告)号：US20240174666A1

公开(公告)日：2024-05-30

申请号：US18457795

申请日：2023-08-29

Applicant: Array BioPharma Inc.

Inventor： Ronald Jay Hinklin ,  Shelley Allen ,  Patrick Michael Doerner Barbour ,  Adam Wade Cook ,  Joshua Ryan Dahlke ,  John Joseph Gaudino ,  Ellen Ruth Laird ,  Oren Teague McNulty ,  Qian Zhao

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Provided herein are compounds of the Formula I:




and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.

公开(公告)号：US11834453B2

公开(公告)日：2023-12-05

申请号：US17362580

申请日：2021-06-29

Applicant: Array BioPharma Inc.

Inventor： Mark Laurence Boys ,  Bryan Daniel Ellis ,  John Joseph Gaudino ,  Erik James Hicken ,  Ellen Ruth Laird ,  Nicholas Charles Lazzara ,  Bradley Jon Newhouse ,  Spencer Phillip Pajk

IPC: A61K31/519 ,  C07D487/04 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07D519/00

Abstract: This invention relates to compounds of Formula (I):




and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US11634409B2

公开(公告)日：2023-04-25

申请号：US17745346

申请日：2022-05-16

Applicant: Array BioPharma Inc.

Inventor： Patrick Michael Barbour ,  Katie Keaton Brown ,  Adam Wade Cook ,  Erik James Hicken ,  Dean Russell Kahn ,  Ellen Ruth Laird ,  Andrew Terrance Metcalf ,  David Austin Moreno ,  Bradley Jon Newhouse ,  Spencer Phillip Pajk ,  Brett Joseph Prigaro ,  Li Ren ,  Eugene Tarlton

IPC: C07D403/12 ,  C07D239/90 ,  C07D239/91 ,  A61K31/4184 ,  A61K45/06

Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.